Tumor angiogenesis has become an important field of research over the past decade due to its crucial role in the growth and spread of cancer. Significant amount of literature has demonstrated the link between tumor angiogenesis, metastasis, and prognosis. Not all tumors are angiogenesis-derived and the angiogenesis switch is a sign of the ability of tumor and inflammatory cells to produce angiogenesis factors in tumor microenvironment. Endothelial cell genetic stability plays an important role in this phenomenon as it makes it less likely to build up resistance towards agents aimed at tumor vasculature. Furthermore, since a minor 0.05% of the adult human body undergoes angiogenesis at any given moment, the potential side effects of anti-angiogenesis treatments is minimal. This study focuses on the role of and methods of modulating angiogenesis in tumor development.
Introduction
Cancer is a very complicated disease characterised by uncontrolled, unregulated cell growth. Cancer happens when abnormal cells grow to such an extent that they synthesize their own blood vessels (angiogenesis) and break free from the tumor and start spreading to other body systems. is process, called metastasis, is what characterizes cancer. ere are many other mechanistic process that develops caner including in ammatory cytokines, and anti-apoptotic cancer biomarkers.
e ultimate goal of all micro-mechanism is further supported when cancer builds new blood vessels for itself. e cancer sends cancer cells out through the lymphatic system or through the blood stream and the newly established micro-metastasis goes through the process of angiogenesis. Cancer cells get nutrients through the blood vessels and it can grow and grow until it sends further cancer cells through the body to spread the cancer further. Each time this angiogenesis smartly involved to harmonize the entire cancer cell metabolic systems. us, understanding angiogenesis and its mechanical process is crucial for the development of new treatment.
Angiogenesis
Angiogenesis refers to the formation of new capillary blood vessels from pre-existing ones. It is vital for normal development, growth of the organism, and in the physiological processes of wound healing, placenta formation, and in tumor growth (Folkman J, 2002; Mangi and Newland 2008) .
e initiation of angiogenesis begins with the local release of proand anti-angiogenesis growth factors by endothelial cells (ECs).
ese released biomolecules di use into the surrounding tissue and bind to speci c cell-surface receptors located on quiescent, (Duarte et al., 2004; Gri oen et al., 2000) .
e term angiogenesis was rst used to describe the formation of new blood vessels in the placenta 8 decades ago. It was then identi ed in wound healing and tumor growth. One study
proposed that inhibition of angiogenesis may be a potential way of treating cancer as it can inhibit cancer progression (Folkman J, 2002 ).
e impact of tumor angiogenesis and the tumor microenvironment has been extensively studied in solid tumors ( Figure 1 ). It was found, for instance, that the appropriate balance between anti-angiogenic and pro-angiogenic signals that arise from stromal and tumor cells in response to cell-ECM and/or direct cell-cell binding, as well as the response to paracrine and autocrine growth factor stimulation, is lost during tumorigenesis (Fan et al., 2012) . e aforementioned angiogenic switch, which is a rapid increase of blood vessel formation in order to support cancer growth, is triggered by several factors (Hoeben et al., 2004; . ese are metabolic stress, genetic mutations, immune response, hypoxia (as well as oncogene-mediated tumor expression of antigenic proteins like platelet derived growth factor), broblast growth factor, vascular endothelial growth factor, endothelial growth factor, angiopoietin, and lysophosphatic acid (Weidner et al., 1993) .
e main mechanism of cancer angiogenesis is endothelial sprouting that depends on vascular endothelial growth factor upregulation and the interaction between endothelial cells, pericytes, and stroma cells, as well as extracellular matrix ( Figure   2 ) (Gri oen et al., 2000; Hoeben et al., 2004; .
Vascular endothelial growth factor and angiopoietin activate matrix degrading enzymes to loosen the matrix, in turn favours endothelial cells migration (Sang, 1998; McMahon, 2000) . A key mediator of angiogenic response is hypoxia-inducible factor-1 (HIF-1), which is responsible for the transcriptional activation of a number of growth factors such as vascular endothelial growth factor (VEGF). Other genes that are induced by hypoxia-inducible factors are platelet derived growth factor, epidermal growth factor receptor, insulin-like growth factor 2, stromal cell-derived factor 1, glucose transporter 1, transforming growth factor-β, tumour growth factor α, activin B and carbonic anhydrase 9 McMahon , 2000) . e hypoxia-inducible factor is also regulated by oxygen-independent pathways through growth-factor receptors or signalling molecules. HIF-1α synthesis is triggered by signalling molecules, and growth factors, as well as loss of function mutations in molecules like p53, PTEN, and VHL. A recent study found that miR424, a unique microRNA in hypoxic endothelial cells, promotes hypoxia-inducible factor-1 stabilization, and angiogenesis (Ghosh et al., 2010) . Besides being a key regulator of angiogenesis, hypoxia-inducible factor is required for cancer cell proliferation, survival, invasion, migration, metabolism, drug resistance, pH regulation, radiation resistance, and genetic stability, as well as immune evasion (Hirota and Semenza, 2006) .
Sprouting and Non-sprouting Angiogenesis
Angiogenesis includes the sprouting, pruning branching, and di erential growth of blood vessels to form the more mature-look- On the other hand, non-sprouting angiogenesis occurs via the enlargement and splitting of existing vessels with transcapillary posts or pillars of extracellular matrix (Burri et al., 2004) . is takes place through in situ proliferation of endothelial cells in order to form a wide lumen (Figure 2 ). e wide lumen is then split by transcapillary pillars. Non-sprouting can occur concurrently with sprouting angiogenesis in the vascularization of tissues or organs like heart, lung and yolk sac during development (Yano et al., 2003) . e mechanism of non-sprouting angiogenesis in respect to tumor metastasis is not yet known. However, vascular endothelial growth factor, which is also known as vascular permeability factor, is said to play an important role in the development, and in physiological and pathological neovascularization (Folkman, 2002) .
Both the sprouting and non-sprouting angiogenesis or intussusception form a functional extraembryonic vasculature (Figure 3 ). e sprouting angiogenesis accounts for a major contribution to the functional vascularization of certain organs like the brain . e nonsprouting angiogenesis serves as a major mechanism for the formation of embryonic lung vasculature (Ribatti and Crivellato, 2012) . e sprouting and non-sprouting angiogenesis are said to contribute to an increasing complexity of the growing vascular network. e network assembles and matures through the recruitment of smooth muscle cells and pericytes. Eventually, it allows a directional ow of blood.
Morphogenic events leading to a mature vascular network involved a few additional steps like vessel assembly, maturation, acquisition of vessel identity as well as organotypic di erentiation (Ribatti and Crivellato, 2012) .
Angiogenesis Mediators
Angiogenic growth factors and cytokines are the mediators of angiogenesis (Owen et al., 2013) . Among the most commonly 
The Role of Angiogenesis in Solid Tumours
Solid tumors are not able to grow over a few millimeteres without angiogenesis . is statement is further supported Folkman and his co-workers started to work on angiogenesis four decades ago, and postulated that solid tumors are angiogenesis-dependent. is initiated a great deal of research relative to angiogenesis and tumor biology. Consequently, over the past 30 years, around 17,000 papers have been published on the angiogenic process and its role in solid tumors (Nicosia et al., 1998) .
e role of angiogenesis in solid tumors has been proven when it was demonstrated that the microvascular density of bone marrow increased signi cantly in multiple myeloma in comparison to monoclonal gammopathy (Zou et al., 2010) . e microvascular density of bone marrow also increased in active multiple myeloma compared to non-active myeloma (Vacca et al., 2001 ).
In multiple myeloma mass, angiogenesis favors the expansion of the tumor by promoting plasma cell proliferation (Ria et al., 2003) . Myeloma plasma cells promotes angiogenesis directly through the secretion of angiogenic cytokines (Giuliani et al., 2011) .
Likewise, in a study which comprised 51 children with acute 
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Figure 3 | Non-sprouting angiogenesis (Kurz et al. 1996) lymphocytic leukaemia, the microvascular density in bone marrow was found to increase six-to-seven fold in comparison to control group bone marrow of children evaluated for primary tumors (Alexandrakis et al., 2004) .
Urinary levels of broblast growth factor-2, (FGF-2) were higher in children with acute lymphocytic leukaemia before induction therapy, which were normalized a er therapy. FGF-2 is a mediator of angiogenesis. is provided evidence that angiogenesis is essential for tumor growth. ese ndings were further supported by the ndings by List, 2001 , who found increased bone marrow microvascular density in acute lymphocytic leukaemia.
e investigation also identi ed increased plasma levels of FGF-2 in acute lymphocytic leukaemia patient, but VEGF did not increase (List, 2001 ).
Anti-angiogenesis as Therapeutic Agent in Cancer
Blood vessels of tumors di er from normal resting blood vessels.
e di erence of special tumor blood vessels makes them reliable targets for tumor-directed treatment (Dudley, 2012) . Moreover, anti-angiogenic therapeutic agents may act by neutralizing the angiogenic proteins, inhibiting synthesis of angiogenic proteins by cancer cells, directly inducing endothelial cell apoptosis or inhibiting endothelial receptors for angiogenic proteins ( Figure   4 ). e anti-angiogenic inhibitors include small molecules and therapeutic antibodies that are capable of targeting angiogenic growth factors like bFGF and VEGF or angiogenic growth factor receptors like PDGFR and VEGFR. (Daly, 2003) . e anti-angiogenic e cacy of the therapeutic agents is best observed when used in low dosages on a frequent or continuous schedule. Metronomic chemotherapy is de ned by the frequent administration of chemotherapeutic agents at doses below the maximum tolerated doses with no prolonged drug-free breaks (Maiti, 2014) . In reference to this, it was found that the main targets of metronomic chemotherapy were the endothelial cells involved in the expanding vasculature of a tumor. Besides reducing acute toxicity, the e cacy of metronomic chemotherapy seems to increase when used in combination with certain antiangiogenic therapeutic agents (Ma and Waxman, 2008) . Several studies showed that endothelial cells of newly forming blood vessel capillaries are highly sensitive to low doses of chemotherapeutic drugs.
ese studies involved microtubule inhibitors like paclitaxel, docetaxel and vinblastine (Kerbel and Kamen, 2004 ).
e use of anti-angiogenic agents to normalize tumor vasculature is an emerging concept to improve the e cacy of radiotherapy and cytotoxic chemotherapy (Loges et al., 2010) . Likewise, it has been found that anti-angiogenic agents can normalize tumor vasculature and hence improve delivery of cytotoxic agents administered during the normalization window (Goe et al., 2011) . ( Gaulin et al., 2009) . Bevacizumab is a monoclonal antibody, which acts on vascular endothelial growth factor. It was later found to assist in halting tumor growth and metastasis by blocking tumor angiogenesis (Duignan et al., 2011) .
Another e ective anti-angiogenic drug that has been approved is a ibercept. A ibercept is formed from the combination of two VEGFR1 and three VEGFR2 within the Fc region of IgG1 (Moroney et al., 2009) . is fusion protein allows a ibercept to block the activity of VEGF at very low lwvels. In addition, a ibercept has a long half-life, which allows long-term tumor angiogenesis blockage (Semeraro et al., 2013) . A ibercept caused signicant tumor regression in pre-clinical studies and decreased tumor vascularity. In addition, Sunitinib acts an an ATP-competitive inhibitor of PDGFRs, FLT3, VEGFR1, VEGFR2 , VEGFR3, RET and c-Kit. ese activities lead to the inhibition of tumor growth, progression, angiogenesis, and metastasis (Cai et al., 2011) .
Anti-angiogenesis from Plant Origin
Scientists have been looking for angiogenesis inhibitors and promoters from natural products for the past een years. is may be due to the potential of natural product to act through multiple cell-signaling pathways and decrease the development of resistance by cancer cells. erefore a number of angiogenesis inhibitors derived from plant were screened in order to study their potential as anti-angiogenesis inhibitors.
A study to the anti-angiogenic properties of pterogynidine alkaloid, derived from Alchorneaglandulosa, was carried out using human umbilical vein endothelial cells. It was found that there was an increase in apoptosis, signi cant decrease in tumor proliferation, as well as invasion capacity when the pterogynidine alkaloid was used. In addition, pterogynidine alkaloid also caused a drastic reduction in the number of capillary-like structures formation in the tumor. is showed that pterogynidine can be used to treat pathological situations like tumor development (Sureram et al.,2012) .
Likewise, Raga et al., 2011 studied the anti-angiogenic properties of the leaf extracts of Ardisiapyramidalis. It was found that the methanol extract of the leaf was antiangiogenic as it showed statistically signi cant lower blood vessels count in comparison to the negative control and untreated eggs. It was concluded that Ardisiapyramidalis can be used as a chemotherapeutic agent for cancer therapy (Raga et al., 2011) Tylophorine has also been identi ed as a potential anti-angiogenic agent for cancer therapy. Tylophorine is a phenanthraindolizidine alkaloid, which was isolated from Tylophoraindica. It was found that Tylophorine exerts antitumour and antiangiogenic properties by targeting vascular endothelial growth factor receptor 2, which is a mediator of angiogenesis. It inhibits a series of VEGF-induced angiogenesis processes, including migration and proliferation, as well as tube formation of endothelial cells.
Tylophorine also inhibits VEGF-stimulated in ammatory responses that include TNF-alpha, IFN-gamma, IL6, IL-8, MMP-2 and NO secretion. Hence, the study concluded that Tylophorine is a viable drug for cancer therapy due to its anti-angiogenesis e ects through VEGFR2 signalingpathway (Saraswati et al., 2013) . e essential oil isolated from Tridaxprocumbens L. has shown promising activity on lung metastasis by inhibiting tumor nodule formation.
e formation of tumor-directed new blood vessels was also inhibited with the use of this essential oil. e investigation demonstrated further that this essential oil signi cantly induced apoptosis and suppressed angiogenesis in tumor cells.
Hence, Tridaxprocumbens L can be useful to help prevent lung metastasis in lung cancer cell (B16F-10), due to its antiangiogenesis e ect and its ability to induce apoptosis (Manjamalai and Grace, 2013 (Risinger et al., 2009 ).
Plant-derived polyphenols have been studied for several years for their anti-angiogenic properties. Red wine polyphenols were found to have a unique dual e ect that provides important therapeutic properties for the treatment of cancer (Baron-Menguy et al., 2007) . In high doses, red wine polyphenols exhibit anti-angiogenic e ects through the mediation of PI3k-Akt-eNOS pathways and potential MMP modulation. On the other hand, Resveratrol, a plant derivative, is able to inhibit tumor-induced neovascularisation as a result of blockage of both bFGFreceptor and VEGF mediated responses involving MAPK phosphorylation (Gupta et al., 2010) . e application of red wine and green tea polyphenols into the chick embryo choroallantoic membrane were shown to signi cantly inhibit angiogenesis. Green tea polyphenols were also found to diminish tumor growth, tumor cell proliferation, and microvessel density. In addition, infusions of green tea polyphenols were able to reduce angiogenesis and metastasis markers like VEGF (Khan and Mukhtar, 2010 
